Curaleaf International Extends Device Availability to New Zealand

Curaleaf International, part of Curaleaf Holdings, Inc., announced an Australian first involving a TGA-registered liquid medical cannabis inhalation device, according to PR Newswire. The announcement was made in partnership with Jupiter Research LLC.

PR Newswire reported that Curaleaf International also extended availability to New Zealand. The release identifies the product as a liquid medical cannabis inhalation device and connects the Australian registration with the New Zealand availability update.

Australian registration and New Zealand availability

According to PR Newswire, Curaleaf International secured registration with the TGA for the liquid medical cannabis inhalation device in Australia. The publisher characterized the development as an Australian first.

The same announcement said availability was extended to New Zealand. Curaleaf International and Jupiter Research LLC are the organizations named in the PR Newswire release.

The update places an Australian regulatory development alongside availability in New Zealand. PR Newswire described Curaleaf International as part of Curaleaf Holdings, Inc.

Commercial update for medical sales audiences

For pharmaceutical and medical sales professionals following medical cannabis products, the announcement focuses on a liquid medical cannabis inhalation device across Australia and New Zealand. The reported developments concern TGA registration in Australia and extended availability in New Zealand.

PR Newswire did not provide further product or market details in the supplied summary. The available information identifies the device, the Australian registration, the New Zealand availability extension, and the partnership with Jupiter Research LLC.

Announcement highlights

• Curaleaf International announced a TGA-registered liquid medical cannabis inhalation device in Australia.
• PR Newswire characterized the Australian development as a first.
• The announcement was made in partnership with Jupiter Research LLC.
• Availability was extended to New Zealand.